Charles River Laboratories International, Inc. (NYSE:CRL) will look for M&A. President and Chief Executive Officer James Foster said, "we will continue to invest aggressively from an organic point of view but also through M&A to continue to expand portfolio scientifically and geographically so that we can be a more holistic provider. it will continue to be a major area of focus, a major area of investment and probably continue to be an area of further M&A investment as well. we will continue to do M&A to the extent to which we find good targets".
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
227.8 USD | -4.85% | +0.11% | -3.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.63% | 11.7B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+46.62% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
+7.30% | 11.1B | |
-18.79% | 9.85B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International Mulls M&A